You open the results expecting a familiar set of numbers. Instead, your cholesterol has moved in the wrong direction.
Perhaps you have been following the food and movement changes we discussed in Part 2. Perhaps you are still figuring out what is realistic while working, caring for family, and trying to get through the night. Either way, another instruction to “eat better and exercise” may not answer the question you actually have: What do I do now?
I want that question to lead to a conversation, not a verdict about your effort. The next step should explain what changed, what it means for your health, and which options belong in your plan.
The Short Version
Understand the change: Compare current results with earlier ones, but do not overlook a cholesterol level that has stayed high.
Bring your reproductive history: Pregnancy complications and early menopause belong in the cardiovascular conversation, not just the gynecology chart (2026 guideline discussion).
Separate the treatment goals: Relief of menopause symptoms and reduction of cardiovascular risk need coordinated decisions, not an assumption that one treatment solves both.
Leave with a written plan: Know your goal, what you are trying, and when you will reassess.
A Change Worth Understanding, Not Blaming
In the Study of Women’s Health Across the Nation, or SWAN, increases in LDL cholesterol and ApoB accelerated around the final menstrual period rather than following a uniform age-related rise (SWAN lipid study). That makes “What has changed since your last test?” a more useful opening than “What have you been doing wrong?”
LDL cholesterol measures cholesterol carried in LDL particles; ApoB helps assess the number of particles that can contribute to plaque (2026 dyslipidemia guideline). If you remember our transit analogy, those are related questions about the cargo and the vehicles carrying it. The trend matters, but so do the level you have reached and your overall risk.
In that SWAN analysis, larger LDL increases around menopause were associated with more carotid artery plaque later on, but this was an observational study, not proof that every woman with a midlife increase needs medication (SWAN lipid study). My takeaway is to investigate the change rather than dismiss it as “just menopause.”
Nor should menopause become the explanation for everything: an underactive thyroid can also raise cholesterol, and the Endocrine Society recommends checking for that cause before starting lipid-lowering treatment (Endocrine Society guidance). I also want to review your earlier results and anything you have started or stopped taking. The explanation should come from the assessment, not your age alone.
Your Reproductive History Belongs in This Visit
Tell me more than when your periods became irregular. Tell me whether you had preeclampsia, high blood pressure during pregnancy, gestational diabetes, or a preterm delivery, and whether menopause occurred unusually early.
The 2026 ACC/AHA multisociety dyslipidemia guideline recognizes early menopause before age 45 and adverse pregnancy outcomes as information that can help personalize cardiovascular risk assessment (2026 guideline discussion). These details do not automatically dictate a prescription. They help us decide whether a seemingly reassuring summary leaves something important out.
The guideline uses the PREVENT equations to estimate cardiovascular risk and incorporates longer-term assessment, family history, and other risk markers into treatment decisions (2026 guideline discussion). I want us to distinguish “How likely is a problem soon?” from “What are we trying to prevent over the years ahead?”
Additional testing should have a purpose, not become another assignment:
Lp(a): Current guidance recommends measuring this largely inherited risk marker at least once in adulthood; ask whether it has already been checked (2026 guideline discussion).
ApoB: Selective testing can clarify risk, particularly when triglycerides are elevated, diabetes is present, or cholesterol measurements may not tell the whole story; ask what the result would change (2026 dyslipidemia guideline).
Coronary calcium: For selected women aged 45 or older whose treatment decision remains uncertain after risk assessment, a calcium scan can guide the discussion; it is not a routine test for every woman entering menopause (2026 dyslipidemia guideline).
A calcium score of zero is not an automatic reason to delay treatment: important exceptions include familial hypercholesterolemia or severely elevated LDL, diabetes after age 40, current smoking, and a strong family history of premature atherosclerotic cardiovascular disease (2026 dyslipidemia guideline). A test should help us make a better decision, not give us a reason to ignore the rest of your history.
When a Prescription Belongs in the Plan
Menopause is not, by itself, a prescription for a statin; the decision should reflect your cholesterol levels and overall cardiovascular risk (2026 dyslipidemia guideline). A life stage is not an automatic prescription.
Some findings make treatment much more clearly indicated: LDL cholesterol of 190 mg/dL or higher warrants statin treatment and evaluation for secondary causes; established atherosclerotic cardiovascular disease is a separate indication, as is diabetes in adults aged 40 to 75 (2026 dyslipidemia guideline). Those are different conversations from a modest increase in someone whose overall assessment is reassuring.
Statins reduce major cardiovascular events similarly in women and men at comparable risk (Cholesterol Treatment Trialists’ analysis). The useful question is “Given my risk, how much might treatment help me, and what are its downsides?”
For the broader discussion of cholesterol prescriptions and supplements, including their benefits, limitations, and safety considerations, see The Integrative Cardiologist: “The Cholesterol Transit Authority — Part 3”. Here, I want to focus on what menopause changes about that decision: your risk assessment, where HRT fits, and the plan you make with your clinician.
If you already have aches, fatigue, or difficulty sleeping, tell your clinician before starting a new medicine. New muscle symptoms deserve assessment and, when needed, alternative treatment strategies, not a choice between silently tolerating a problem and abandoning prevention (2026 dyslipidemia guideline).
Where HRT Fits, and Where It Does Not
“If estrogen changes helped cause this, should I replace the estrogen?” That is a reasonable question, but it contains two separate treatment decisions.
Hormone replacement therapy, also called menopausal hormone therapy, is the most effective treatment for hot flashes and night sweats and can prevent bone loss (Menopause Society position statement). Feeling better is a legitimate treatment goal, not a consolation prize.
For otherwise appropriate women younger than 60 or within 10 years of menopause onset, without contraindications, the benefit-risk balance is generally favorable for treating bothersome symptoms (Menopause Society position statement). But “appropriate for symptoms” and “a substitute for cholesterol treatment” are different conclusions.
Better numbers are not the whole outcome
Oral estrogen can lower LDL cholesterol but also raise triglycerides; estrogen delivered through the skin generally has less effect on raising triglycerides and may be preferred when these are elevated (ACC-led hormone-therapy review). This is why your clinician needs to know the exact product and route, not simply that you take “HRT.”
Observational studies suggest a lower risk of venous blood clots with transdermal estrogen than with oral estrogen, but direct randomized comparisons of clot outcomes are lacking (ACC-led hormone-therapy review). A patch is not a declaration of zero risk.
Timing matters, with a more favorable overall profile when therapy begins closer to menopause; nevertheless, hormone therapy is not recommended to prevent cardiovascular disease (ACC-led hormone-therapy review). The Endocrine Society specifically recommends statin therapy rather than hormone therapy for postmenopausal high cholesterol when lipid treatment is indicated (Endocrine Society guidance).
I would coordinate two decisions: What is the right treatment for your menopause symptoms, and what is the right treatment for your cardiovascular risk? The answer may include both hormone therapy and a cholesterol medicine.
Details that change the hormone decision
Your medical history: Prior heart attack, stroke, venous blood clots, estrogen-sensitive cancer, unexplained vaginal bleeding, and liver disease are important contraindications to systemic hormone therapy, not simply reasons to choose a different route (Menopause Society position statement).
Your uterus and treatment type: Systemic estrogen generally requires a progestogen or another approved form of endometrial protection if you have a uterus; low-dose vaginal estrogen for local vaginal and urinary symptoms is a different treatment, with minimal systemic absorption (Menopause Society position statement).
Early loss of ovarian function: For premature or early menopause, including after removal of both ovaries, hormone therapy is generally recommended at least until the usual age of menopause when there is no contraindication (Menopause Society position statement).
Bring these details into the same visit. “Estrogen” is not one interchangeable product, and the cholesterol plan still needs its own assessment.
The Supplement Question Is Still About the Goal
The companion article in The Integrative Cardiologist covers the broader supplement evidence. Here, the question is what, if anything, earns a place in your menopause-specific plan.
The 2026 guideline does not recommend dietary supplements for lowering LDL cholesterol or triglycerides, citing limited or inconsistent evidence and limited benefits (2026 dyslipidemia guideline). That belongs in the conversation before we consider a particular product.
For a product marketed for menopause, I would ask: Was it studied in women like you, and what did the study actually measure? Relief of hot flashes, a lower cholesterol result, and fewer heart attacks are not interchangeable goals.
I want to understand your preference for a supplement, not dismiss it. But any adjunct needs a defined job and an acceptable safety profile; it should not become a reason to postpone treatment that your overall risk calls for.
Bring every bottle, including products marketed for menopause, sleep, or “hormone balance.” Do not make the cholesterol decision in one room and the supplement decision in another.
The Plan You Take Home
Before leaving, ask for a clear next step rather than a longer list of things you “should” do. A useful plan should let you fill in these blanks:
My numbers: My current LDL is ; my ApoB, if relevant, is .
My risk: The parts of my history that change the decision are _.
My goal: We are aiming for _.
My next step: We are working on lifestyle, adding treatment, or changing _ because _.
If we are waiting: The finding or change that would make us reconsider medication is _.
My hormone decision: If HRT is appropriate, the symptoms we are treating are _.
My check-in: We will repeat _ and review the results on _.
After starting or adjusting cholesterol-lowering medication, current guidance recommends a repeat lipid panel in 4 to 12 weeks to assess the response (2026 dyslipidemia guideline). A lifestyle-focused plan also needs an agreed review date. “Try harder and we will see” is not the plan I want you to leave with.
One practical note during perimenopause
HRT does not provide contraception (NHS contraception and menopause guidance). If pregnancy is possible or planned, raise it before choosing cholesterol treatment; the FDA advises that most pregnant patients stop statins under their clinician’s guidance, with individualized exceptions for very high-risk patients (FDA statin guidance).
You do not need to prove that you have exhausted every diet, workout, or supplement before discussing another form of help. You also deserve to understand a prescription before agreeing to it.
The aim is to make room for both how you feel now and the health you want to protect. Your cholesterol changed. The next step is a plan you understand, helped shape, and know how to revisit.
This article is for patient education and does not replace individualized medical advice. Do not start, stop, or change a medication, hormone therapy, or supplement without discussing it with your clinician.
References
Dagen N, McCarthy C, Ramirez V. Prioritizing Health | Lower Sooner: How the 2026 Dyslipidemia Guideline Changes Practice. American College of Cardiology, Cardiology Magazine. July 1, 2026.
Matthews KA, El Khoudary SR, Brooks MM, et al. Lipid Changes around the Final Menstrual Period Predict Carotid Subclinical Disease in Postmenopausal Women. Stroke. 2017;48(1):70–76.
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia. American College of Cardiology/American Heart Association. Published online March 13, 2026.
Endocrine Society. Lipid Management in Patients with Endocrine Disorders. Clinical Practice Guideline. 2020.
Cholesterol Treatment Trialists’ Collaboration. Efficacy and Safety of LDL-Lowering Therapy among Men and Women: Meta-analysis of Individual Data from 174,000 Participants in 27 Randomised Trials. The Lancet. 2015.
Azhak S. The Cholesterol Transit Authority — Part 3: The Prescription, the Supplement, and the Decision between Them. The Integrative Cardiologist. Companion article.
The North American Menopause Society Advisory Panel. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
Cho L, Kaunitz AM, Faubion SS, et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?. Circulation. 2023.
NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board. Contraception and Menopause. Remedy clinical guidance.
U.S. Food and Drug Administration. FDA Requests Removal of Strongest Warning against Using Cholesterol-Lowering Statins during Pregnancy; Still Advises Most Pregnant Patients Should Stop Taking Statins. Drug Safety Communication. July 20, 2021.